Abingworth Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
14
- Investments
-
249
- Portfolio
-
33
- Exits
-
156
Abingworth General Information
Description
Founded in 1973, Abingworth is a venture capital firm headquartered in London, United Kingdom. The firm prefers to invest in seed-stage, early-stage, growth-stage, and later-stage companies. The firm seeks to invest in healthcare, information technology, life science, and technology-based sectors in the United States and Europe.
Contact Information
Website
www.abingworth.com
Year Founded
1973
Investor Status
Actively Seeking New Investments
Trade Association
British Venture Capital Association (BRVCA)
New England Venture Capital Association (NEVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 38 Jermyn Street
- London SW1Y 6DN
- England, United Kingdom
+44 020 0000 0000
Abingworth Investments & Acquisitions (249)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Pathalys Pharma | 18-Jan-2023 | Early Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 3 | |
| 000000000 | 06-Dec-2022 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 000000 00000000 00.0 |
| 0000000 0000000000 | 28-Nov-2022 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 0000000 00.0 |
| 0000000 | 18-May-2022 | 0000 | 000 | Drug Discovery | Generating Revenue/Not Profitable | 0000 0000000000 00.0 |
| 000000 00000000000 | 11-Apr-2022 | 00000 000000 | Other Healthcare Services | Generating Revenue | 0000 000 000000 | |
| 00000000 000000000 | 04-Apr-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 3 | 0000000 000000 |
| 00000 000 | 30-Sep-2021 | 0000 00000 | 00.000 | Other Commercial Products | Stealth | |
| 000000 00000000000 | 24-Sep-2021 | 0000 | 00000 | Drug Discovery | Clinical Trials - Phase 1 | 0000 000 000000 |
| Anjarium Biosciences | 16-Sep-2021 | Later Stage VC | 000.00 | Drug Delivery | Generating Revenue | 0000 0000000000 00.0 |
| HilleVax | 08-Sep-2021 | Early Stage VC | 00000 | Drug Discovery | Generating Revenue/Not Profitable |
Abingworth Exits (156)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Sierra Oncology | 01-Jul-2022 | Merger/Acquisition | 00.00 |
| 00000000 | 29-Apr-2022 | 000 | 00000 |
| 0000 000000000000 | 11-Feb-2022 | 000000 0000000000 | 000.00 |
| 00000000 000000000 | 10-Jan-2022 | 000000000000000000 | |
| 0000000000 0000000 | 27-Oct-2021 | 000000000000000000 | |
| 000000 00000000000 | 24-Sep-2021 | 000000000000000000 | 00000 |
| 00000 0000 0000000 | 22-Sep-2021 | 0000000 000000 | 00000 |
| 00000000 000000000 | 26-Aug-2021 | 0000000 000000 | 00000 |
| Avillion | 01-Jul-2021 | Secondary Transaction - Private | |
| Vera Therapeutics | 14-May-2021 | IPO | 000.00 |
Abingworth Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Abingworth Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Abingworth Team (50)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Neil Cooper | Chief Financial Officer | London, United Kingdom | |||
| Andrew Sinclair Ph.D | Managing Director | 0 | 0 | 0 | London, United Kingdom |
| Jayson Punwani Ph.D | Managing Director | 0 | 0 | 0 | London, United Kingdom |
| Joy Ghosh Ph.D | Managing Director | 0 | 0 | London, United Kingdom | |
| Kurt von Emster | Managing Partner | 00 | 0 | 0 | Menlo Park, CA |
Abingworth Co-Investors (118)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Citadel Enterprise Americas | 5 | 0 |
|
|
|
| Osage University Partners | 0 | 0 | 0 |
|
|
| Alexandria Venture Investments | 0 | 0 | 0 |
|
|
| Omega Funds | 0 | 0 |
|
|
|
| RiverVest Venture Partners | 0 | 0 |
|
|